MAPT and Alzheimer disease: Levels of Aβ, total tau (t-tau), and phosphorylated tau (p-tau) are concurrent with AD pathology [99,100] and indicate its presence; at this stage amyloid [101] and tau PET imaging [102] define the topographical extension of such pathology, while MRI [103] and FDG-PET [104] define the topographical severity of the neurodegenerative process; finally, markers such as p-tau, NfL [105] and YKL40 [106] can be useful, and early, peripheral indicators of disease stage.